Search

 
 
 
As Novartis Buys In to Gene Therapy, GSK Bows Out with Orchard Deal

AS NOVARTIS BUYS IN TO GENE THERAPY, GSK BOWS OUT WITH ORCHARD DEAL

Novartis just bet close to $9 billion on the future of gene therapy, a boost for a field that hasn't yet seen commercial success. In...

 
 
 
Novartis just handed out a $8.7 billion endorsement for new therapies that are changing how we treat genetic diseases

NOVARTIS JUST HANDED OUT A $8.7 BILLION ENDORSEMENT FOR NEW THERAPIES THAT ARE CHANGING HOW WE TREAT GENETIC DISEASES

Novartis is acquiring gene therapy company AveXis for $8.7 billion. AveXis is working on a gene therapy for spinal muscular atrophy,...

 
 
 
 
 
 
Biotech Roundup: Opioid News, ASH Preview, Boston Bio IPOS & More

BIOTECH ROUNDUP: OPIOID NEWS, ASH PREVIEW, BOSTON BIO IPOS & MORE

The rising death toll from opioids has prompted policymakers to try various ways to take on the problem. President Trump's opioid commission...

EARLY DATA WIN FOR AVEXIS' SMA TYPE 1 THERAPY BUT BIOGEN'S MED ALSO STRONG

Early data win for AveXis' SMA Type 1 therapy but Biogen's med also strong badams Sun, 10/09/2016 - 05:52